<DOC>
	<DOC>NCT00759135</DOC>
	<brief_summary>This completed study evaluated the safety and efficacy of two dose levels of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) versus finasteride.</brief_summary>
	<brief_title>Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)</brief_title>
	<detailed_description>Subjects randomized to NX-1207 were blinded as to the dose level of NX-1207 they received.</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Finasteride</mesh_term>
	<criteria>1. Documented history of BPH for at least 1 year 2. AUA SI ≥ 15 3. Prostate Volume ≥ 30 mL ≤ 70 mL 4. Qmax &lt; 15 mL/sec 1. History of illness or condition that may interfere with study or endanger subject 2. Use of prescribed medications that may interfere with study or endanger subject 3. Presence of a median lobe of the prostate 4. Surgery or MIST in the previous 12 months for treatment of BPH 5. Postvoid residual urine volume &gt; 350 mL 6. PSA ≥ 10 ng/mL; prostate cancer must be ruled out for PSA ≥ 4 ng/mL</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>BPH</keyword>
	<keyword>Enlarged Prostate</keyword>
</DOC>